연구동향 분석
박사

Discovery of Inhibitors of a Protein?RNA (Lin28-let-7) Interaction and Antimalarial Agents Through the Development of High-Throughput Screening : 고효율 생리활성 탐색 방법의 개발을 통한 단백질?RNA 상호작용 저해제 및 항말라리아 화합물의 발굴

임동현 2015년

논문상세정보
인용/피인용
' Discovery of Inhibitors of a Protein?RNA (Lin28-let-7) Interaction and Antimalarial Agents Through the Development of High-Throughput Screening : 고효율 생리활성 탐색 방법의 개발을 통한 단백질?RNA 상호작용 저해제 및 항말라리아 화합물의 발굴' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • high-throughput screening
  • malaria
  • protein-rna interaction
  • small molecule
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
96 0

0.0%

' Discovery of Inhibitors of a Protein?RNA (Lin28-let-7) Interaction and Antimalarial Agents Through the Development of High-Throughput Screening : 고효율 생리활성 탐색 방법의 개발을 통한 단백질?RNA 상호작용 저해제 및 항말라리아 화합물의 발굴' 의 참고문헌

  • a) Zock, J. M. Applications of high content screening in life scienceresearch. Comb. Chem. High Throughput Screening Comb. Chem. High. T. Scr.262009, 12, 870?876; b) Zanella, F.; Lorens, J. B.; Link W. High contentscreening: seeing is believing. Trends Biotechnol. 2010, 28, 237?245; c)Soleilhac, E.; Nadon, R.; Lafanechere, L. High-content screening for thediscovery of pharmacological compounds: advantages, challenges andpotential benefits of recent technological developments. Expert Opin. DrugDiscovery 2010, 5, 135?144.
  • a) Vinogradov, E.; Bock, K. A new type of glycosidic linkage: an openchainacetal-linked N-acetylgalactosamine in the core part of thelipopolysaccharides from Proteus microorganisms. Angew. Chem. Int. Ed.1999, 38, 671?674 ; b) Hindsgaul, O. Carbohydrate chemistry: Sugars out inthe open. Nature 1999, 399, 644?645.
  • a) Schreiber, S. L. Target-oriented and diversity-oriented organic synthesisin drug discovery. Science 2000, 287, 1964?1969; b) Burke, M. D.; Schreiber,S. L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int.Ed. 2004, 43, 46?58; c) Spandl, R. J.; Bender, A.; Spring, D. R. Diversityorientedsynthesis; a spectrum of approaches and results. Org. Biomol. Chem.2008, 6, 1149?1158; d) Galloway, W. R. J. D.; Isidro-Llobet, A.; Spring, D. R.Diversity-oriented synthesis as a tool for the discovery of novel biologicallyactive small molecules. Nat. Commun. 2010, 1, 80; e) O’Connor, C. J.;Beckmann, H. S. G.; Spring, D. R. Diversity-oriented synthesis: producingchemical tools for dissecting biology. Chem. Soc. Rev. 2012, 41, 4444?4456.
  • a) Schreiber, S. L. Small molecules: the missing link in the central dogma.Nat. Chem. Biol. 2005, 1, 64?66; b) Hubel, K; Lessmann, T; Waldmann, H.Chemical biology?identification of small molecule modulators of cellularactivity by natural product inspired synthesis. Chem. Soc. Rev. 2008, 37,1361?1374.
  • a) Sauer, W. H. B.; Schwarz, M. K. Molecular shape diversity ofcombinatorial libraries:& a prerequisite for broad bioactivity. J. Chem. Inf.Comput. Sci. 2003, 43, 987?1003; b) Kopp, F.; Stratton, C. F.; Akella, L. B.;Tan, D. S. A diversity-oriented synthesis approach to macrocycles viaoxidative ring expansion. Nat. Chem. Biol. 2012, 8, 358?365.
  • a) Sagar, R.; Park, S. B. Facile and efficient synthesis of carbohybrids asstereodivergent druglike small molecules. J. Org. Chem. 2008, 73, 3270?3273;b) Sagar, R.; Kim, M. J.; Park, S. B. An improved synthesis of pyrimidine- andpyrazole-based acyclo-C-nucleosides as carbohybrids. Tetrahedron Lett. 2008,49, 5080?5083.
  • a) Oh, S.; Kim, S. J.; Hwang, J. H.; Lee, H. Y.; Ryu, M. J.; Park, J.; Kim,S. J.; Jo, Y. S.; Kim, Y. K.; Lee, C. H.; Kweon, K. R.; Shong, M.; Park, S. B.Antidiabetic and antiobesity effects of ampkinone (6f), a novel small moleculeactivator of AMP-activated protein kinase. J. Med. Chem. 2010, 53, 7405?7413; b) Oh, S.; Nam, H. J.; Park, S.; Beak, S. H.; Park, S. B. Development ofa benzopyran-containing androgen receptor antagonist to treat antiandrogenresistantprostate cancer. ChemMedChem 2010, 5, 529?533; c) Zhu, M.; Kim,M. H.; Lee, S.; Bae, S. J.; Kim, S. H.; Park, S. B. Discovery of novelbenzopyranyl tetracycles that act as inhibitors of osteoclastogenesis inducedby receptor activator of NF-κB ligand. J. Med. Chem. 2010, 53, 8760?8764; d)Oh, S.; Cho, S.W.; Yang, J. Y.; Sun, H. J.; Chung, Y. S.; Shin, C. S.; Park, S.B. Discovery of a novel benzopyranyl compound as a potent in vitro and invivo osteogenic agent. MedChemComm 2011, 2, 76?80; e) Cho, T.-J.; Kim, J.;Kwon, S.-K.; Oh, K.; Lee, J.-a.; Lee, D.-S; Cho, J.; Park, S. B. A potentsmall-molecule inducer of chondrogenic differentiation of human bonemarrow-derived mesenchymal stem cells. Chem. Sci. 2012, 3, 3071?3075.
  • a) Lehμr, J.; Stockwell, B. R.; Giaever, G.; Nislow, C. Combinationchemical genetics. Nat. Chem. Biol. 2008, 4, 674?681; b) O’Connor, C. J.;Laraia, L.; Spring, D. R. Chemical genetics. Chem. Soc. Rev. 2011, 40, 4332?4345.
  • a) Ko, S. K.; Jang, H. J.; Kim, E.; Park, S.B. Concise and diversityorientedsynthesis of novel scaffolds embedded with privileged benzopyranmotif. Chem. Commun. 2006, 2962?2964; b) Lee, S. C.; Park, S. B. Novelapplication of Leuckart?Wallach reaction for synthesis of tetrahydro-1,4-benzodiazepin-5-ones library. Chem. Commun. 2007, 3714?3716; c) Sagar, R.;27Park, J.; Koh, M.; Park, S. B. Diastereoselective synthesis of polycyclic acetalfusedpyrano[3,2-c]pyran-5(2H)-one derivatives. J. Org. Chem. 2009, 74,2171?2174; d) Kim, J.; Song, H.; Park, S. B. Orthogonal regioselectivesynthesis of N-Alkyl-3-substituted tetrahydroindazolones. Eur. J. Org. Chem.2010, 3815?3822.
  • a) Klefel, M. J.; von Itzstein, M. Recent advances in the synthesis of sialicacid derivatives and sialylmimetics as biological probes. Chem. Rev. 2002, 102,471?490; b) Angata, T.; Varki, A. chemical diversity in the sialic acids andrelated α-keto acids:& an evolutionary perspective. Chem. Rev. 2002, 102, 439?469.
  • a) Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. M. Privileged structures: auseful concept for the rational design of new lead drug candidates. Mini-Rev.Med. Chem. 2007, 7, 1108?1119 ; b) Welsch, M. E.; Snyder, S. A.; Stockwell,B. R. Privileged scaffolds for library design and drug discovery. Curr. Opin.Chem. Biol. 2010, 14, 347?361.
  • a) Drewry, D. H.; Macarron, R. Enhancements of screening collections toaddress areas of unmet medical need: an industry perspective. Curr. Opin.Chem. Biol. 2010, 14, 289?298; b) Marcaurelle, L. A.; Foley, M. A. Theevolving role of molecular diversity in drug discovery. Curr. Opin. Biol. 2010,14, 285?288.
  • a) Dandapani, S.; Marcaurelle, L. A. Grand challenge commentary:accessing new chemical space for 'undruggable' targets. Nat. Chem. Biol. 2010,6, 861?863; b) Schreiber, S. L. Organic synthesis toward small-moleculeprobes and drugs. P. Natl. Acad. Sci. USA 2011, 108, 6699?6702.
  • a) Carmona, A. T.; Fuentes, J.; Robina, I.; Garcia, E. R.; Demange, R.;Vogel, P.; Winters, A.L. Stereoselective syntheses of 1,4-dideoxy-1,4-iminooctitolsand novel tetrahydroxyindolizidines. J. Org. Chem. 2003, 68, 3874?3883; b) Lundt, I.; Steiner, A. J.; Stutz, A. E.; Tarling, C. A.; Ully, S.; Withers,S. G.; Wrodnigg, T. M. Fluorescently tagged iminoalditol glycosidaseinhibitors as novel biological probes and diagnostics. Bioorg. Med. Chem.2006, 14, 1737?1742.
  • a) Bekhit, A. A.; Hymete, A.; Bekhit, A. E. A.; Damtew, A.; Aboul-Enein,H. Y. Pyrazoles as promising scaffold for the synthesis of anti-inflammatoryand/or antimicrobial agent: a review. Mini-Rev. Med. Chem. 2010, 10, 1014?291033; b) Parameswaran, P. S.; Naik, C. G.; Hegde, V. R. Secondarymetabolites from the sponge Tedania anhelans: &isolation and characterizationof two novel pyrazole acids and other metabolites. J. Nat. Prod. 1997, 60,802?803; c) Lagoja, I. M. Pyrimidine as constituent of natural biologicallyactive compounds. Chem. Biodiversity 2005, 2, 1?50; d) Sirichaiwat, C.;Intaraudom, C.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Thebtaranonth,Y.; Yuthavong, Y. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wildtype and mutant dihydrofolate reductases from Plasmodium falciparum. J.Med. Chem. 2004, 47, 345?354; e) Weitzel, K. W.; Wickman, J. M.; Augustin,S. G.; Strom, J. G. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent forthe treatment of insomnia. Clin. Ther. 2000, 22, 1254?1267.
  • a) Baindur, N; Chadha, N.; Player, M. R. Solution-phase synthesis of alibrary of 3,5,7-trisubstituted 3H-[1,2,3]triazolo[4,5-d]pyrimidines. J. Comb. Chem. 2003, 5, 653?659; b) Wang, P. Y.; Du, J. F.; Rachakonda, S.; Chun, B. K.; Tharnish, P. M.; Stuyver, L. J.; Otto, M. J.; Schinazi, R. F.; Watanabe, K. A. Synthesis and structure?activity relationships of novel anti-hepatitis CAgents: N3,5’-Cyclo-4-(β-d-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-onederivatives. J. Med. Chem. 2005, 48, 6454?6460 ; c) Gao, Y. N.; Lam, Y. L. [3+2] Cycloaddition reactions in the synthesis of triazolo[4,5-b]pyridin-5-onesand pyrrolo[3,4-b]pyridin-2-ones. J. Comb. Chem. 2008, 10, 327?332; d)Majumdar, K. C.; Ray, K. Synthesis of 1,2,3-triazole-fused heterocycles viaintramolecular azide-alkyne cycloaddition reactions. Synthesis-Stuttgart 2011,3767?3783; e) Donald, J. R.; Wood, R. R.; Martin, S. F. Application of asequential multicomponent assembly process/Huisgen cycloaddition strategyto the preparation of libraries of 1,2,3-triazole-fused 1,4-benzodiazepines. ACS30Comb. Sci. 2012, 14, 135?143; f) Fosso, M. Y.; Chan, K. Y.; Gregory, R.;Chang, C. W. T. Library synthesis and antibacterial investigation of cationicanthraquinone analogs. ACS. Comb. Sci. 2012, 14, 231?235.
  • Zuker, M. Mfold web server for nucleic acid folding and hybridizationprediction. Nucleic Acids Res. 2003, 31, 3406?3415.
  • Zhou, J. B.; Ng, S. B.; Chng, W. J. LIN28/LIN28B: An emergingoncogenic driver in cancer stem cells. Int. J. Biochem. Cell B. 2013, 45, 973?978.
  • Zhao, S. High-performance liquid chromatographic determi- nation ofartemisinine (qinghaosu) in human plasma and saliva. Analyst 1987, 112,661?664.
  • Zhang, Y.; Asante, K. S.; Jung, A. Stage-dependent inhibition ofchloroquine on Plasmodium falciparum in vitro. J. Parasitol. 1986, 72,830?836.
  • Young, T. S.; Ahmad, I.; Yin, J. A.; Schultz, P. G. An enhanced systemfor unnatural amino acid mutagenesis in E. coli. J. Mol. Biol. 2010, 395, 361?374.
  • White, N. J. Clinical pharmacokinetics and pharmacodynamics ofartemisinin and derivatives. Trans. R. Soc. Trop. Med. Hyg. 1994, 88, 41?43.
  • Wells, T. N.; Alonso, P. L.; Gutteridge, W. E. New medicines to improvecontrol and contribute to the eradication of malaria. Nature Rev. DrugDiscovery 2009, 8, 879?891.
  • Viswanathan, S. R.; Daley G. Q.; Gregory, R. I. Selective blockade ofMicroRNA processing by Lin28. Science 2008, 320, 97?100.
  • Verma, R.; Khanna, P.; Chawla, S. Malaria vaccine can prevent millions ofdeaths in the world. Hum. Vaccines Immunother. 2013, 9, 1268?1271.
  • Velagapudi S. P.; Gallo S. M.; Disney M. D. Sequence-based design ofbioactive small molecules that target precursor microRNAs. Nat. Chem. Biol.2014, 10, 291?297.
  • Trang, P.; Medina P. P.; Wiggins J.F.; Ruffino L.; Kelnar K.; Omotola, M.;Homer, R.; Brown, D.; Badaer, A.G.; Weidhaas, J.B.; Slack, F. J. Regressionof murine lung tumors by the let-7 microRNA. Oncogene 2010,29: 1580?1587.
  • Thornton J. E.; Gregory, R.I. How does Lin28 let-7 control developmentand disease? Trends Cell Biol. 2012, 22, 474?482.! 84
  • Swinney, D. C.; Anthony J. How were new medicines discovered? Nat.Rev. Drug. Discov. 2011, 10, 507?519.
  • Soni, S.; Dhawan, S.; Rosen, K. M.; Chafel, M.; Chishti, A. H.; Hanspal,M. Characterization of events preceding the release of malaria parasite fromthe host red blood cell. Blood Cells, Mol., Dis. 2005, 35, 201?211.
  • Singh, K.; Kaur, H.; Smith, P.; de Kock, C.; Chibale, K.; Balza- rini, J.Quinoline?pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, andmode of action studies. J. Med. Chem. 2014, 57, 435?448.
  • Searle, P. A.; Richter, R. K.; Molinski, T. F. Bengazoles C?G from thesponge Jaspis sp. synthesis of the side chain and determination of absolute28donfiguration. J. Org. Chem. 1996, 61, 4073?4079.
  • Sanz, L. M.; Crespo, B.; De-Cozar, C.; Ding, X. C.; Llergo, J. L.;Burrows, J. N.; Garcia-Bustos, J. F.; Gamo, F. J. P. falciparum in vitro killingrates allow to discriminate between different antimalarial mode-of-action.PLoS One 2012, 7, e30949.
  • Salmon, B. L.; Oksman, A.; Goldberg, D. E. Malaria parasite exit fromthe host erythrocyte: a two-step process requiring extraerythrocytic proteolysis.Proc. Natl. Acad. Sci. USA 2001, 98, 271?276.
  • SNU3701 and SNU3662 are identical to compound 11b and 3d,respectively, in ref 18.
  • Piskounova, E.; Viswanathan, S. R.; Janas, M.; LaPierre, R.J.; Daley, G.Q.;Sliz, P.; Gregory, R. I. (2008) Determinants of microRNA processinginhibition by the developmentally regulated RNA-binding protein Lin28. J.Biol. Chem. 2008, 283, 21310?21314.
  • Piskounova, E.; Polytarchou, C.; Thornton, J. E.; LaPierre, R. J.;Pothoulakis, C.; Hagan, J. P.; Illiopoulos, D.; Gregory, R. I. (2011) Lin28Aand Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell2011, 147, 1066?1079.
  • Olliaro, P.; Wells, T. N. The global portfolio of new antimalarial medicinesunder development. Clin. Pharmacol. Ther. 2009, 85, 584?595.
  • Oh, S.; Park, S.B. A design strategy for drug-like polyheterocycles withprivileged substructures for discovery of specific small-molecule modulators.Chem. Commun. 2011, 47, 12754?12761.
  • O'Donoghue, P.; Ling, J. Q.; Wang, Y.S.; Soll, D. Upgrading proteinsynthesis for synthetic biology. Nat. Chem. Biol. 2013, 9, 594?598.
  • Noedl, H.; Se, Y.; Schaecher, K.; Smith, B. L.; Socheat, D.; Fukuda, M.M. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J.Med. 2008, 359, 2619?2620.
  • Nam, Y.; Chen, C.; Gregory, R. I.; Chou, J. J.; Sliz, P. Molecular basis forinteraction of let-7 microRNAs with Lin28. Cell 2011, 147, 1080?1091.
  • Naik, R. S.; Krishnegowda, G.; Gowda, D. C. Glucosamine inhibitsinositol acylation of the glycosylphosphatidylinositol anchors inintraerythrocytic Plasmodium falciparum. J. Biol. Chem. 2003, 278,2036?2042.
  • Murray, C. J.; Rosenfeld, L. C.; Lim, S. S.; Andrews, K. G.; Foreman, K. J.;Haring, D.; Fullman, N.; Naghavi, M.; Lozano, R.; Lopez, A. D. Globalmalaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012,379, 413?431.
  • Muregi, F. W.; Wamakima, H. N.; Kimani, F. T. Novel drug targets inmalaria parasite with potential to yield antimalarial drugs with long usefultherapeutic lives. Curr. Pharm. Des. 2012, 18, 3505?3521.! 118
  • Moon, S.; Lee, S.; Kim, H.; Freitas-Junior, L. H.; Kang, M.; Ayong, L.;Hansen, M. A. An image analysis algorithm for malaria parasite stageclassification and viability quantification. PLoS One 2013, 8, e61812.
  • Mayr, F.; Schutz, A.; Doge, N.; Heinemann, U. The Lin28 cold-shockdomain remodels pre-let-7 microRNA. Nucleic Acids Res. 2012, 40, 7492?7506.
  • Marras S. A. E.; Kramer, F. R.; Tyagi, S. Efficiencies of fluorescenceresonance energy transfer and contact-mediated quenching in oligonucleotideprobes. Nucleic Acids Res. 2002, 30, e122.
  • Lopez Del Prado, G. R.; Hernan Garcia, C.; Moreno Cea, L.; FernandezEspinilla, V.; Munoz Moreno, M. F.; Delgado Marquez, A.; Polo Polo, M. J.;! 117Andres Garcia, I. Malaria in developing countries. J. Infect. Dev. Countries2014, 8, 1?4.
  • Liu, C. C.; Schultz, P. G. Adding new chemistries to the genetic code.Annu. Rev. of Biochem. 2010, 79, 413?444.
  • Lim, D.; Park, S. B. Synthesis of molecular frameworks containing twodistinct heterocycles connected in a single molecule with enhanced threedimensionalshape diversity. Chem. Eur. J. 2013, 19, 7100?7108.! 119
  • Krishna, S.; White, N. J. Pharmacokinetics of quinine, chloroquine andamodiaquine. Clinical implications. Clin. Pharmacokinet. 1996, 30, 263?299.
  • Klonis, N.; Crespo-Ortiz, M. P.; Bottova, I.; Abu-Bakar, N.; Kenny, S.;Rosenthal, P. J.; Tilley, L. Artemisinin activity against Plasmodium falciparumrequires hemoglobin uptake and digestion. Proc. Natl. Acad. Sci. USA 2011,108, 11405?11410.
  • Klonis, N.; Creek, D. J.; Tilley, L. Iron and heme metabolism inPlasmodium falciparum and the mechanism of action of artemisinins. Curr.! 120Opin. Microbiol. 2013, 16, 722?727.
  • Kelly, G. E.; Lindsey, J. K. Robust estimation of the median lethal dose. J.Biopharm. Stat. 2002, 12, 137?147.
  • Huntzinger, E.; Izaurralde, E. Gene silencing by microRNAs: contributionsof translational repression and mRNA decay. Nat. Rev. Genet. 2011, 12, 99?110.
  • Hung, A. W.; Ramek, A.; Wang, Y. K.; Kaya, T.; Wilson, J. A.; Clemons,P. A.; Young, D. W. Route to three-dimensional fragments using diversityorientedsynthesis. Proc. Natl. Acad. Sci. USA 2011, 108, 6799?6804.
  • Heo, I.; Joo, C.; Kim, Y.-K.; Ha, M.; Yoon, M.-J.; Cho, J.; Yeom, K.-H.;Han, J.; Kim, V. N. TUT4 in concert with Lin28 suppresses microRNAbiogenesis through pre-microRNA uridylation. Cell 2009, 138, 696?708.
  • Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol.Cell Bio. 2014, 15, 509?524.
  • Grimberg, B. T.; Mehlotra, R. K. Expanding the antimalarial drugarsenal?now, but how? Pharmaceuticals (Basel) 2011, 4, 681?712.
  • Greenwood, B. M.; Fidock, D. A.; Kyle, D. E.; Kappe, S. H.; Alonso, P. L.;Collins, F. H.; Duffy, P. E. Malaria: progress, perils, and prospects foreradication. J. Clin. Invest. 2008, 118, 1266?1276.
  • Gligorijevic, B.; Purdy, K.; Elliot, D.; Cooper, R. A.; Roepe, P. D. Stageindependent chloroquine resistance and chloroquine toxicity revealed viaspinning disk confocal microscopy. Mol. Biochem. Parasitol. 2008, 159, 7?23.
  • Enserink, M. If artemisinin drugs fail, what’s plan B? Science 2010, 328,846.
  • Dondorp, A. M.; Yeung, S.; White, L.; Nguon, C.; Day, N. P.; Socheat, D.;von Seidlein, L. Artemisinin resistance: current status and scenarios forcontainment. Nature Rev. Microbiol. 2010, 8, 272?280.
  • Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.;Lwin, K. M.; Ariey, F.; Hanpithakpong, W.; Lee, S. J.; Ringwald, P.; Silamut,K.; Imwong, M.; Chotivanich, K.; Lim, P.; Herdman, T.; An, S. S.; Yeung, S.;Singhasivanon, P.; Day, N. P.; Lindegardh, N.; Socheat, D.; White, N. J.Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med.2009, 361, 455?467.
  • Dommerholt, J.; Schmidt, S.; Temming, R.; Hendriks, L. J. A.; Rutjes, F.P. J. T; van Hest, J. C. M.; Lefeber, D. J.; Friedl, P.; van Delft, F. L. Readilyaccessible bicyclononynes for bioorthogonal labeling and three-dimensionalimaging of living cells. Angew. Chem. Int. Ed. 2010, 49, 9422?9425.! 85
  • Desjardins, A.; Bouvette, J.; Legault, P. Stepwise assembly of multipleLin28 proteins on the terminal loop of let-7 miRNA precursors. Nucleic AcidsRes. 2014, 42, 4615?4628.
  • Delves, M. J.; Ruecker, A.; Straschil, U.; Lelievre, J.; Marques, S.;Lopez-Barragan, M. J.; Herreros, E.; Sinden, R. E. Male and femalePlasmodium falciparum mature gametocytes show different responses toantimalarial drugs. Antimicrob. Agents Chemother. 2013, 57, 3268? 3274.
  • Cridge, A.G.; Major, L. L.; Mahagaonkar, A. A.; Poole, E. S.; Isaksson, L.A.; Tate, W.P. Comparison of characteristics and function of translationtermination signals between and within prokaryotic and eukaryotic organisms.Nucleic Acids Res. 2006, 34, 1959?1973.
  • Cong, F.; Cheung, A. K.; Huang, S. M. A. Chemical genetics?based targetidentification in drug discovery. Annu. Rev. Pharmacol. 2012, 52, 57?78.
  • Chang, H. T.; Sharpless, K. B.; A practical route to enantiopure 1,2-aminoalcohols. Tetrahedron Lett. 1996, 37, 3219?3222.
  • Chang, H. M.; Triboulet, R.; Thornton, J. E.; Gregory, R. I. A role for thePerlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. Nature2013, 497, 244?248.
  • Chang, H. H.; Moss, E. L.; Park, D. J.; Ndiaye, D.; Mboup, S.; Volkman, S.K.; Sabeti, P. C.; Wirth, D. F.; Neafsey, D. E.; Hartl, D. L. Malaria life cycleintensifies both natural selection and random genetic drift. Proc. Natl. Acad.Sci. USA. 2013, 110, 20129?20134.
  • Burke, M. D.; Berger, E. M.; Schreiber, S. L. Generating diverseskeletons of small molecules combinatorially. Science 2003, 302, 613?618.
  • Burchard, G. D. [Malaria - update 2013]. MMW?Fortschr. Med. 2013, 155,42?44.
  • Buechner, J.; Tomte E.; Haug, B. H.; Henriksen, J. R.; Lokke, C.; Fl gstad,T.; Einvik, C. Tumour-suppressor microRNAs let-7 and mir-101 target the! 83proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplifiedneuroblastoma. Brit. J. Cancer 2011, 105, 296?303.
  • Berres, M. An effective method for the estimation and comparison of theED50 with small sample sizes. J. Exp. Anim. Sci. 1991, 34, 21?29.